NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CLRB

Cellectar Biosciences Inc

May 19 • 01:42PM ET

0.2526

Dollar change +0.0076
Percentage change 3.10	%

Healthcare • Biotechnology • USA • NASD

Peers: KPTI GLYC APTO CLLS IMUX ONCT MEIP CRIS PSTV SLS

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	1.67%	Shs Outstand	46.08M	Perf Week	-4.35%
Market Cap	11.64M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	4.06%	Shs Float	45.31M	Perf Month	-15.52%
Income	-24.54M	PEG	-	EPS next Q	-0.14	Inst Own	11.42%	Short Float	3.45%	Perf Quarter	-19.58%
Sales	0.00M	P/S	-	EPS this Y	53.01%	Inst Trans	17.15%	Short Ratio	1.60	Perf Half Y	-87.91%
Book/sh	0.17	P/B	1.51	EPS next Y	-9.88%	ROA	-83.27%	Short Interest	1.56M	Perf Year	-92.48%
Cash/sh	0.30	P/C	0.84	EPS next 5Y	19.07%	ROE	-208.72%	52W Range	0.22 - 3.42	Perf YTD	-15.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.27%	ROI	-244.91%	52W High	-92.61%	Beta	0.50
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.77%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	2.47	EPS Y/Y TTM	81.80%	Oper. Margin	-	RSI (14)	44.40	Volatility	7.68% 7.59%
Employees	11	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.33	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	84.21%	Payout	-	Rel Volume	0.62	Prev Close	0.25
Sales Surprise	-	EPS Surprise	14.27%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	976.21K	Price	0.25
SMA20	-5.71%	SMA50	-14.75%	SMA200	-76.24%	Trades		Volume	405,115	Change	3.10%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-24	Resumed	Ladenburg Thalmann	Buy	$13
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy	$10
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy	$2.70

May-14-25 03:30AM	Q1 2025 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 07:05AM	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) -9.13%
May-07-25 08:05AM	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 (GlobeNewswire)
Apr-30-25 08:05AM	Cellectar Announces Plan to Explore Strategic Alternatives (GlobeNewswire) -13.54%
08:52AM	Loading…
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +5.58%
Mar-18-25 09:40AM	Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? (Zacks) +11.97%
Mar-14-25 03:04AM	Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +5.34%
Mar-13-25 11:43PM	Q4 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.37%
07:05AM	Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update (GlobeNewswire)
Mar-11-25 08:05AM	Cellectar Biosciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-05-25 08:05AM	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 (GlobeNewswire) +6.56%
Feb-05-25 08:05AM	Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-25 06:00PM	Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 11:25AM	Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options (Benzinga) -76.16%
05:00PM	Loading…
Dec-10-24 05:00PM	Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring (GlobeNewswire) -5.19%
Nov-21-24 08:00AM	NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) (Business Wire)
Nov-19-24 01:39AM	Q3 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.04%
Nov-18-24 07:05AM	Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update (GlobeNewswire)
Nov-14-24 08:05AM	Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 (GlobeNewswire)
Nov-12-24 08:05AM	Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer (GlobeNewswire)
Nov-11-24 04:05PM	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 (GlobeNewswire)
Nov-07-24 06:40AM	Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 (GlobeNewswire)
Nov-01-24 05:00PM	Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q (GlobeNewswire)
Aug-26-24 06:40AM	Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia (GlobeNewswire)
Aug-23-24 05:00PM	Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq (GlobeNewswire)
Aug-13-24 06:40AM	Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update (GlobeNewswire) +8.60%
Aug-08-24 05:15PM	UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
04:05PM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
Jul-23-24 06:40AM	Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months (GlobeNewswire) -18.54%
06:40AM	Loading…
Jul-22-24 06:40AM	Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million (GlobeNewswire) +19.84%
Jun-27-24 06:40AM	Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape (GlobeNewswire) -19.38%
May-29-24 06:40AM	Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides (GlobeNewswire)
May-15-24 08:18AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.66%
03:43AM	Q1 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-14-24 10:53AM	CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update (GlobeNewswire)
May-08-24 06:40AM	Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day (GlobeNewswire)
May-07-24 06:40AM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 (GlobeNewswire)
Mar-28-24 10:33AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.49%
Mar-27-24 10:09PM	Q4 2023 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.58%
10:53AM	CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update (GlobeNewswire)
Mar-20-24 06:40AM	Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 (GlobeNewswire)
Mar-14-24 08:52AM	Cellectar Biosciences to Present at the 36th Annual Roth Conference (GlobeNewswire)
Mar-04-24 06:40AM	Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer (GlobeNewswire)
Feb-07-24 06:40AM	Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-24 06:40AM	Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study (GlobeNewswire) -5.70%
Jan-25-24 06:40AM	Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million (GlobeNewswire) +6.85%
Jan-22-24 06:40AM	Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient (GlobeNewswire)
Jan-16-24 06:40AM	Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data (GlobeNewswire) +5.41%
Jan-12-24 06:44AM	Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results (GlobeNewswire)
Jan-11-24 06:40AM	Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting (GlobeNewswire)
Jan-08-24 08:37AM	Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today? (InvestorPlace) +18.08%
06:40AM	Cellectar's blood cancer therapy succeeds in trial (Reuters)
06:30AM	Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia (GlobeNewswire)
Jan-03-24 08:30AM	Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 (GlobeNewswire)
Dec-19-23 08:30AM	Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation (GlobeNewswire)
Dec-12-23 08:30AM	Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform (GlobeNewswire)
Dec-05-23 08:30AM	Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire)
Nov-04-23 12:36PM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 07:30AM	Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024 (GlobeNewswire)
Oct-25-23 08:00AM	Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting (GlobeNewswire)
Oct-24-23 08:00AM	Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023 (GlobeNewswire)
Oct-17-23 08:00AM	Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia (GlobeNewswire)
Oct-02-23 06:35AM	Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants (GlobeNewswire) +8.33%
Sep-18-23 08:40AM	Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstroms Macroglobulinemia (GlobeNewswire)
Sep-11-23 06:30AM	Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing (GlobeNewswire)
Sep-05-23 08:21AM	Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing (GlobeNewswire) +36.26%
Aug-14-23 08:40AM	Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update (GlobeNewswire)
Jun-30-23 09:40AM	Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year? (Zacks) +5.41%
Jun-28-23 08:30AM	Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting (GlobeNewswire)
Jun-12-23 08:30AM	Cellectar Provides a Research and Development Program Summary (GlobeNewswire)
May-04-23 09:22AM	UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update (GlobeNewswire)
08:40AM	Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update (GlobeNewswire)
Mar-09-23 08:40AM	Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update (GlobeNewswire) -10.53%
Mar-08-23 04:05PM	Cellectar to Participate at Upcoming Banking Conferences (GlobeNewswire)
Feb-28-23 08:30AM	Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient (GlobeNewswire)
Feb-15-23 08:30AM	Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical (GlobeNewswire)
Nov-30-22 08:30AM	Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer (GlobeNewswire)
Nov-21-22 08:30AM	Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference (GlobeNewswire)
Nov-16-22 08:30AM	Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute (GlobeNewswire)
Nov-03-22 08:30AM	Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update (GlobeNewswire) -6.86%
Oct-25-22 04:30PM	Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -5.21%
Oct-21-22 08:30AM	Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.14%
Sep-22-22 08:30AM	Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors (GlobeNewswire) -9.05%
Sep-13-22 08:30AM	Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Natures Blood Cancer Journal (GlobeNewswire)
Aug-30-22 02:55PM	Will Cellectar Biosciences (NASDAQ:CLRB) Spend Its Cash Wisely? (Simply Wall St.)
Aug-05-22 08:30AM	Cellectar Reports Financial Results for Second Quarter 2022 (GlobeNewswire)
Jul-21-22 04:15PM	Cellectar Announces Stock Consolidation (GlobeNewswire) +5.43% -20.60%
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
May-10-22 08:30AM	Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update (GlobeNewswire) -8.06%
Apr-26-22 08:00AM	Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstroms Macroglobulinemia (GlobeNewswire) -6.32%
Apr-12-22 08:30AM	Cellectar Biosciences Announces Key Commercial Team Appointments (GlobeNewswire)
Mar-23-22 06:35PM	Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-21-22 08:30AM	Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update (GlobeNewswire) +15.81%
Mar-10-22 04:05PM	Cellectar to Participate at Upcoming Banking Conferences (GlobeNewswire)
Feb-23-22 08:00AM	Cellectar Biosciences Announces Executive Leadership Changes (GlobeNewswire)
Jan-17-22 09:40AM	Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year? (Zacks)

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Longcor Jarrod	Chief Operating Officer	Jan 10 '25	Buy	0.28	30,000	8,400	83,141	Mar 12 09:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLRB

Cellectar Biosciences Inc

Upgrade your FINVIZ experience